Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for prevention of radiotherapy-induced nausea and vomiting
IRCT20170814035697N7Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nausea and Vomiting and post-radiation nausea and vomiting (RINV) comparing Olanzapine plus usual antiemetic treatment with Placebo plus usual antiemetic treatment (2 arms). Primary endpoint: nausea and vomiting. Started Jan 2022; status: completed.
02
Drugs
olanzapine
03
Conditions
Nausea and Vomitingpost-radiation nausea and vomiting (RINV)
Beyond the preview
Go deeper on IRCT20170814035697N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170814035697N7.